Systemic lupus erythematosus (SLE) is a complex autoimmune disease with contribution from genetic, environmental, immunoregulatory, hormonal, and epigenetic factors. 1 The development of SLE occurs when there is a loss of self-tolerance, propagated by poor clearance of apoptotic bodies, and the subsequent development of antinuclear antibodies. This, along with immune complex formation, cytokine production, and activation of complement, leads to end organ damage. Kidney involvement, termed lupus nephritis (LN), 1 of the most critical manifestations of SLE, occurs in approximately 50% of patients with SLE. 2 While clinical outcomes overall have improved for LN, a large number of patients still go on to develop end-stage kidney disease and outcomes remain poor among certain ethnic groups, notably African Americans. 3, 4 The treatment of LN has experienced a slow evolution since the introduction of corticosteroids in the 1950s. Cyclophosphamide therapy was added in the 1970s and then mycophenolate mofetil became available in the 2000s. After decades of research, nonspecific immunosuppressive regimens remain the core of LN treatments. Newer strategies for therapy with better efficacy and less toxicity are long overdue. In recent years, several more specific biologic agents have been tested, many of which target specific inflammatory pathways. However, after more than a decade of clinical trials, none have been shown to have added efficacy in LN compared to standard of care. 5 This is likely in part due to poor patient selection due to inadequate current biomarkers. The pathogenesis of LN is complex with genetic and environmental contributions leading to altered immune regulation and local inflammation. For an individual patient, 1 pathway may be contributing more to the disease process than another. Biomarkers identifying the pathways upregulated in an individual patient may help identify the best therapy for that patient, making precision medicine a reality in the treatment of LN.
What is a biomarker?. Biomarkers have been defined as biological characteristics that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or response to intervention. 6 Ideal LN biomarkers will (1) identify those at risk for developing disease, (2) distinguish between active and chronic disease, (3) guide choice and duration of therapy, and (4) be easily reproducible in a commercially available assay at a reasonable cost.
CLASSIC BIOMARKERS
The diagnostic standard for LN is a kidney biopsy. The kidney biopsy, however, is invasive, and only provides a single "snapshot" of an evolving pathogenic process. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification system for LN was created in 2004 and has replaced the former World Health Organization classification system. 7 The classification system is focused on glomerular changes on light microscopy and divides LN into 6 classes (Table I) . One of the drawbacks of the ISN/RPS system is that it does not include tubulointerstitial injury or vascular lesions that are both risk factors for disease progression. [8] [9] [10] [11] [12] The ISN/RPS classification system also provides limited information on disease activity. Some pathologists continue to report the NIH Activity and Chronicity Index score, but this is not universally used. 13 An international nephropathology working group recently proposed updates to the ISN/RPS classification system to address the limitations with the current system. 14 This will need to be validated in practice and studies to evaluate whether immunosuppression can be tailored to activity index are needed.
Current laboratory values such as serum creatinine, proteinuria, and hematuria remain important clinical and diagnostic biomarkers for LN. The presence of proteinuria and hematuria determines referral for initial kidney biopsy. Serum creatinine elevation is often a late finding, occurring only after the accrual of significant renal damage, making it unsatisfactory as an initial biomarker. Patients with a history of LN may have elevations in creatinine due to progression of fibrosis rather than flare. Repeat biopsy studies demonstrate discordance between clinical renal remission (defined by resolution of proteinuria and hematuria) and histologic remission (defined by low activity index on kidney biopsy). 15, 16 Malvar et al demonstrated that nearly one-third of patients with clinical renal remission continued to have histologic evidence of lupus activity while a large number of patients with histologic remission (62%) had continued clinical activity. 15 Of the classic biomarkers, proteinuria appears to be the strongest predictor of long-term renal outcome. Longterm follow-up of LN patients in 2 large European Trials Active or inactive diffuse, segmental or global endo-or extracapillary glomerulonephritis involving 50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. This class is divided into diffuse segmental (IV-S) lupus nephritis when 50% of the involved glomeruli have segmental lesions, and diffuse global (IV-G) lupus nephritis when 50% of the involved glomeruli have global lesions. Segmental is defined as a glomerular lesion that involves less than half of the glomerular tuft. This class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation Class V Membranous Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations Class V lupus nephritis may occur in combination with class III or IV in which case both will be diagnosed Class VI Advanced sclerosing 90% of glomeruli globally sclerosed without residual activity
Adapted from Weening et al "The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited." 7 demonstrated proteinuria at 1 year was the best predictor of long-term renal outcome. 17, 18 Further studies are needed to evaluate whether this measure may help stratify patients and guide length of immunosuppressive therapy.
AUTOANTIBODIES
Antinuclear antigens. The production of antibodies against nuclear antigens is the hallmark of SLE. Antinuclear antibodies are highly sensitive, but less specific, especially at low titers. Antinuclear antibodies can also be elevated in other autoimmune conditions and are further characterized by subtypes of extractable nuclear antibodies. Extractable nuclear antibodies include antibodies to Smith (Sm), Ro (SS-A), La (SS-B), ribonucleoprotein (RNP), histones, and double-stranded DNA (dsDNA). Of these, anti-dsDNA is the most specific for SLE and LN.
Anti-dsDNA. Anti-dsDNA antibodies were first identified over 50 years ago and have remained both ubiquitous and contested since their discovery. 19 The predictability of anti-dsDNA in the development of nephritis is complicated by heterogeneity in testing, isotype, and cross reactivity of the antibody to protein antigens. The most commonly available clinical lab tests include immunofluorescence (ie, Crithidia lucilae) and enzyme-linked immunosorbent assays (ELISAs). The Farr assay for antidsDNA is a radioimmunoassay in which serum is incubated with radio-labeled dsDNA followed by the addition of ammonium sulfate for immune complex precipitation. 20 Ammonium sulfate precipitation, dissociates immune complexes of low avidity, leaving only high avidity antibodies, making the test highly specific. 21 Several studies have demonstrated increases in antidsDNA proceeding SLE and LN flare, anti-dsDNA have been eluted from nephritic kidneys, and animal models have demonstrated pathogenicity of antidsDNA. 22, 23 Conversely, not all patients who have anti-dsDNA antibodies develop nephritis and a small percentage of patients with nephritis do not have antibodies to dsDNA. [24] [25] [26] Julkunen et al found the positive predictive value of anti-dsDNA varied between 11% and 16% while the negative predictive value was 86%À91%, in a cohort of 223 patients with SLE. 25 Moroni et al found the positive and negative predictive value of anti-dsDNA to predict LN flares to be 31% and 91%, respectively, in a prospective longitudinal study of 228 patients with LN. 26 The nephritogenic properties of anti-dsDNA antibodies have been attributed to 3 potential mechanisms: (1) glomerular binding of preformed immune complexes of anti-dsDNA and nucleosomes, (2) binding of anti-dsDNA to chromatin or nucleosomes that have become "planted antigens" glomerular basement membrane (GBM), and (3) binding of anti-dsDNA to native "cross reactive" antigens in the glomerulus. [27] [28] [29] To date, there has not been a clinical test that is able to differentiate nephritogenic isoforms of anti-dsDNA from non-nephritogenic forms.
Glomerular antigens. Several glomerular antigens have been identified as potential targets of autoantibodies in LN, including cross reactive with anti-dsNA or antinucleosome antibodies. These include cell-specific targets and proteins found on the GBM (Table II) . The identification of glomerular antigens provides insight into the pathogenesis of LN. Unfortunately, no assay has been validated in multicenter cohorts.
Alfa-actinin. The alfa-actinins are a family of 4 actin binding proteins of which isoforms 1 and 4 are expressed in the glomerulus. 30, 31 Mutations in alfaactinin-4 lead to podocytopathy and familial focal segmental glomerulosclerosis. 32 Glomerular alfa-actinin can be targeted by anti-dsDNA. 33, 34 Lupus prone (MRL/lpr) mice have high levels of circulating antibodies to alfa-actinin that can bind to both alfa-actinin 1 and 4.
31 Nonautoimmune (BALB/c) mice immunized with alfa-actinin develop anti-alfa-actinin antibodies and develop immune complex glomerulonephritis and proteinuria. 35 Antibodies binding alfa-actinin have been identified in patients with LN. [36] [37] [38] Annexins. Annexin autoantibodies have been implicated in a number of autoimmune diseases including SLE and antiphospholipid antibody syndrome and was recently reviewed by Iaccarino et al 39 The annexin family 39, 40 They are involved in a number of cell processes including apoptosis, calcium signaling, cell growth, division, and vesicle trafficking. 39 Annexin A1 (ANXA1) is a ubiquitous protein, present in immune cells and resident glomerular cells. In immune cells, ANXA1 helps regulate innate and adaptive immune responses. 39, 41 Circulating IgM and IgG antibodies to ANXA1 were initially identified in patients with SLE and the IgM isotype correlated with activity level. 42 Bruschi et al identified IgG2 antibodies to ANXA1 in the glomeruli obtained from LN patient biopsy specimens and identified the same isoform in the sera of LN patients. 43 Annexin A2 (ANXA2) is expressed in glomerular mesangial cells, endothelial cells, and epithelial cells. 44, 45 The function of ANXA2 varies with cell type and cellular location. In epithelial cells, such as podocytes, ANXA2 plays a critical role in dynamic remodeling of the actin cytoskeleton. 44, 46 ANXA2 on the cell surface interacts with beta 2-glycoprotein I and toll-like receptor 4, leading to proinflammatory and prothrombotic effects, which may be enhanced by autoantibody binding.
47 AA2 has been identified as an autoantibody in primary and secondary antiphospholipid antibody syndrome. 39 Multiple groups have independently identified ANXA2 as a target for autoantibodies in LN. 45, 48, 49 Cross reactivity of antidsDNA with mesangial ANXA2 has been reported, and ANXA2 colocalizes with glomerular IgG and C3 deposits in LN 45 Our group demonstrated that patients with class III and/or IV LN, but not class V LN have elevated autoantibodies to ANXA2. 48 Alfa enolase. Alfa enolase is a multifunctional protein and its location in the cell helps determine its function. 50 Intracellularly, it serves as a glycolytic enzyme while it acts as a plasminogen receptor on the cell surface. 50 Antibodies to alfa enolase have been identified in multiple immune-mediated kidney diseases including LN, mixed cryoglobulinemia, and primary membranous nephropathy. 43, 51, 52 It has been proposed that exposure to alfa enolase may initially occur in the setting of neutrophil extracellular trap (NET) formation. 41 NET formation, termed NETosis, is a unique form of cell death utilized by neutrophils to entrap microbes. In NETosis, the plasma membrane ruptures releasing strands of chromatin decorated with neutrophil granular proteins as well as other intracellular proteins. 53 A proteomic analysis of isolated human NETs identified nuclear proteins, granule proteins, and other intracellular proteins including alfa enolase. 54 NETosis is a key player in the development of SLE and LN. [55] [56] [57] [58] [59] SLE patients with impaired degradation of NETs are more likely to have LN and hypocomplementemia. 55, 60 GBM proteins. Autoantibodies may bind to proteins within the GBM directly or to nucleosomes which have become "planted antigens" bound to GBM proteins. 28, [61] [62] [63] Nucleosomes have demonstrated a high affinity for negatively charged laminin, heparan sulfate, and collagen IV. [63] [64] [65] A recent study demonstrated that nucleosomes bind avidly to aberrantly expressed laminin b1in human LN. 63 Autoantibodies binding heparan sulfate have been identified in both animal models and human LN. 61, 66 While multiple glomerular antigen targets have been proposed, no clinical test exists for measuring glomerular autoantibodies in LN. While it is reassuring that many of the antigens have been identified by different centers with an ethnically diverse range of patients, no standardized approach has been utilized. While some centers have measured cross reactive anti-dsDNA, others have looked at reactivity alone. Additionally, isotype specificity may be critical for some autoantibodies. 41 In the future, a panel of glomerular autoantibodies might help identify patients with LN.
COMPLEMENT PATHWAY
The complement system includes 3 activation pathways: the classical pathway, alternative pathway, and the lectin pathway. The classical pathway is activated when C1q binds to IgM or IgG in immune complexes. The alternative pathway is spontaneously activated by a conformational change to C3. The lectin pathway is activated when mannose binding lectin binds to carbohydrate groups which are found on microorganisms. All 3 pathways have been implicated in LN. [67] [68] [69] Activation of each pathway leads to the generation of C5b-9, also known as the membrane attack complex (MAC), which forms pores in the membranes of target cells, causing cell activation and lysis. 70 Complement is a "doubleedged sword" in SLE as genetic complement deficiencies are strongly associated with the development of SLE while complement activation plays a key role in perpetuating the disease. [71] [72] [73] Serum C3 and C4 measurements are readily available as clinical tests and can be used alone or within an integrated disease activity score such as the SLE Disease Activity Index (SLEDAI) score. 74 The SLEDAI score is a composite score of serum C3 and C4 measurements along with more than 20 other weighted variables to support the clinical assessment of disease activity within the preceding 10 days. 75 C4 is a component of the classical pathway, which is triggered when C1q binds to immune complexes. C3 is a component of the alternative pathway. Studies to determine how changes in complement levels can serve as SLE or LN flare have yielded variable results. 25, [76] [77] [78] Reduced C3 levels are more predictive of active LN flare. 77, 79 A longitudinal study revealed that reduced C4 levels, 2 months prior to clinical manifestations of LN flare were predictive of future flare, whereas reduced levels of C3 were seen at time of the flare. 79 C1q is a component of the classical complement pathway and is critical for opsonization and clearance of apoptotic bodies and immune complexes. 80 Genetic deficiencies of C1q are rare, but are almost universally associated with SLE like autoimmunity, highlighting poor clearance of apoptotic bodies as an important pathogenic mechanism in the development of SLE. 80, 81 Auto-antibodies to C1q are present in a significant number of SLE patients and correlate strongly with renal involvement. 24, [82] [83] [84] Several studies demonstrated that the predictive value of was enhanced when combined with anti-dsDNA antibodies and/or hypocomplementemia. 26, 82, 83, 85 Orbai et al conducted an international cross-sectional study of anti-C1q in patients with SLE vs rheumatic disease controls from 25 clinical sites to examine the specificity of anti-C1q for SLE and look at the association with nephritis. They found that antiC1q antibodies were present in 28% of patients with SLE vs 13% of disease controls. Further, the anti-C1q was associated with proteinuria (odds ratio [OR] = 3, P < 0.001) and red cell casts (OR = 2.6, P = 0.015). Further, they found that the combination of anti-C1q, anti-dsDNA, and low complement was strongly associated with renal involvement (OR = 14.9, P < 0.01). 82 Moroni et al examined anti-C1q antibodies in a prospective study of 228 patients with LN to evaluate the role of immunologic tests for monitoring LN activity. 26 They found that elevation of anti-C1q antibodies predicted LN flares with 80.5% sensitivity and 71% specificity. This was slightly better than the other individual markers. Anti-C1q combined with C3 and C4 provided the best performance for predicting renal flares at multivariate analysis (P < 0.0005, P < 0.0005, P < 0.005, respectively). Further, the combination of 4 negative tests (negative antibody and normal complement levels) had a high negative predictive value. While their results were promising, they also noted that 46% of nonproliferative (class V) and 20% of proliferative (class III and/or IV) flares were not associated with high anti-C1q levels. 26 A recent retrospective study by Bock et al demonstrated that anti-C1q levels correlated well with global disease activity scores in patients with nephritis, but not in patients without kidney disease. Further they demonstrated a positive correlation between anti-C1q levels and proteinuria and antidsDNA, and a negative correlation with complement levels. 84 Terminal complement activation and formation of C5b-9 (MAC) may contribute to the severity of LN. Lupus prone (MRL/lpr) mice deficient in the complement regulating protein, factor H, demonstrate increased disease severity. 72 Treatment of lupus prone (NZB/W F1) mice with a monoclonal antibody to C5, prevented formation of C5b-9 (MAC), and attenuated LN. 86 Song et al demonstrated elevated serum levels of soluble C5b-9 in patients with active LN when compared to patients with LN in remission, active SLE without nephritis, and normal controls. 69 A recent study demonstrated that C5b-9 (MAC) staining on kidney biopsy is associated with poor clinical response to treatment at 6 months. 87 The combination of anti-dsDNA, anti-C1q, and C3, C4 levels make up a powerful predictive serum biomarker for LN. Unfortunately, the use of anti-C1q measurements in clinical practice has been limited as it is not widely available in commercial laboratories. 88 Initial assays were technically difficult. Emerging multiplex technologies may finally provide an avenue to help facilitate anti-C1q antibody testing. 89 Whether the use of anti-C1q testing improves management of LN patients remains a matter of future research that requires more widespread availability of the test. Terminal complement activation may contribute to the severity of LN. 69, 87 As new anticomplement therapies emerge, markers of terminal complement activation (increased serum levels of soluble C5b-9 and/or increased tissue expression of C5b-9) may help identify those who would benefit most from anticomplement therapy. At this time, there is limited data on the use of anticomplement therapy in LN. Anticomplement therapy been reported successfully in cases of refractory LN, especially in the setting of concomitant thrombotic microangiopathy. 90 
URINARY BIOMARKERS
From both a clinical and pathogenesis standpoint, urine appears to be the "low hanging fruit" of the LN biomarker world. Urine is easy to obtain and real time changes in the inflammatory milieu of the kidney tissue should translate to measurable differences in urine. These observations are hampered by vast differences in processing, which have variable effects on measurable protein levels, lack of uniformity in assays, and lack of agreement regarding whether there should be a "normalization" step. Additional drawbacks include prevailing use of single center cohorts, the use of tests not commercially available for use in the clinical setting, and unintended longitudinal effects of storage buffers in biorepository samples. Many recent studies have moved away from urinary protein abundance levels of individual markers to multimarker panels, urinary protein fragments, urine microRNA, protein levels in urine pellets, and urinary cells.
Neutrophil gelatinase-associated lipocalin. Neutrophil gelatinase-associated lipocalin (NGAL) is a small glycosylated protein produced in many tissues, but initially described in neutrophils. Urine and serum NGAL have been studied extensively as a biomarker in acute kidney injury. 91 In a pediatric lupus cohort, Suzuki et al found that urinary NGAL, but not serum NGAL levels correlated with renal disease activity. 92 In their analysis, they demonstrated that levels increased whether or not they normalized urine NGAL to urine creatinine levels. 92 In a longitudinal study, of 2 ethnically diverse adult SLE cohorts (Bronx, NY; London, UK), urine NGAL level was shown to predict renal activity and was a predictor of flares in patients with known LN. 93 Similarly Satirapoj et al found that with the exception to serum C3 levels urinary NGAL at baseline to be a better predictor of clinical response to treatment of active LN. 94 MCP-1. Monocyte chemoattractant protein 1 (MCP-1) is a leukocyte chemokine that is involved in mediating inflammation in LN. In animal models of LN, blockade of MCP-1 attenuates renal damage. 95 In multiple single center studies, urine MCP-1 level corresponded to LN activity/flare and decreased after disease remission. [96] [97] [98] Further, patients who did not respond to treatment appear to have persistently elevated levels.
96,97
Tumor Necrosis Factor-Like Inducer of Apoptosis. Tumor Necrosis Factor-Like Inducer of Apoptosis (TWEAK) is a member of the TNF superfamily and is a multifunctional cytokine involved in inflammatory, apoptotic, and fibrotic pathways. 99, 100 TWEAK is thought to play a role in the development of LN through increased burden of apoptotic materials and increased inflammation. 99, 100 Urinary TWEAK was evaluated as a biomarker for LN in multicenter cohort study and was found to perform better than antidsDNA and complement levels. 101 Xuejing et al measured urinary TWEAK levels in 46 patients undergoing routine kidney biopsy and found urinary TWEAK levels significantly correlated to the activity index (P < 0.05). 102 Unfortunately, despite promising preclinical studies, 103-105 a phase 2 clinical trial utilizing a TWEAK inhibitor was terminated early after failing to meet primary endpoints. 5 It is unclear if stratification of patients based on urinary TWEAK levels would have had any effect on the results and at this time those data are unavailable.
Lessons learned and longitudinal sample storage affects. Efficient collection and storage of patient samples are required for the study of current and novel urinary biomarkers. A critical component of study success, beyond maintaining constant and continuous storage at ultra-low temperatures, are sample handling and preservation protocols-aliquot volumes, timed vs spot urine samples, addition of inhibitory compounds such as azide or protease inhibitors. A variety of preservatives are used in urine collections including acetic acid, boric acid, hydrochloric acid, toluene, and thymol, each with different effects on substances measured in the urine (https://www.mayo medicallaboratories.com/it-mmfiles/Urine_Preserva tives-Collection_and_Transportation_for_24-Hour_ Urine_Specimens.pdf).
A study by Almaani et al investigated the effects of acetic acid preservative (final concentration 0.5% acetic acid) to the bioreposited samples of patients enrolled in the African American Study of Kidney Disease and Hypertension (AASK) Cohort Study. 106 Prior analysis of AASK patients with overt proteinuria demonstrated high levels of nonalbumin proteinuria, consistent with tubulopathy. Urine bioreposited with the National Institute of Diabetes and Digestive Kidney Diseases was obtained and tested for 7 markers of tubular proteinuria-albumin, ß-2-microglobulin, cystatin-C, osteopontin (OPN), epidermal growth factor, uromodulin, and NGAL. ELISAs for the majority of markers demonstrated poor detectability. The investigators measured these same markers in matched urine samples from patients with LN or healthy black controls. The mean values of 6 of the 7 markers were consistently lower in the AASK-N samples. To determine the effect of sample integrity on the ELISA results, the AASK-N samples were studied by denaturing, reducing polyacrylamide gel electrophoresis. The Coomassie-stained gels demonstrated the loss of well-resolved protein bands and demonstrated severe protein degradation. To determine if the sample collection protocol was the source of the degradation, LN urine samples were adjusted to 0.5% acetic acid and resolved by gel electrophoresis. These test gels produced similar gel images of protein degradation profile as that of AASK-N urine. These data demonstrate the need for increased rigor in establishing biorepository protocols.
Urinary biomarker panels. Urinary biomarker panels have been shown to help identify interstitial inflammation on kidney biopsy and outperformed individual biomarkers in a single center observational study. 107 One recent prospective observational cohort study of adult and pediatric patients demonstrated that a panel of urinary biomarkers performed better at predicting renal function decline than any single biomarker with the most improvement seen in the adult cohort 108 They identified that the combination liver-type fatty acid binding protein, albumin, MCP-1, and transferrin levels had good predictive accuracy of renal function decline in both pediatric (area under the curve [AUC] = 0.82) and adult (AUC = 0.77) cohorts. 108 Antichymotrypsin (ACT) is a serine proteinase inhibitor and has been associated with a number of chronic diseases such as Alzheimers, Parkinsons, and chronic obstructive pulmonary disease but until recently not SLE or LN. 109 Aggrawal et al used a combination of 2-dimensional gel electrophoresis and mass spectrometry to compare the urinary proteome of SLE patients. 110 Disease activity was stratified by SLEDAI. 111 The proteomes of patients with active vs inactive disease were compared and 26 gel spots were selected for MS characterization. Three proteins (ACT, haptoglobin, and retinol-binding protein) were quantified in all patient samples. ACT and haptoglobin were well correlated with renal SLEDAI (r > 0.57 and r > 0.59, respectively). Longitudinal follow-up (6-and 12 months) for patients with active disease demonstrated a loss of all 3 proteins with response to treatment. While haptoglobin and retinol-binding protein have previously been associated with LN this is the first report of ACT as a marker of LN.
The KDIGO and ACR guidelines for treatment of LN recommend change in induction therapy in the absence of a response after 3À6 months, but these recommendations lack consensus on quantitative clinical guidelines for the definition of a failed response. Wolf et al addressed the hypothesis that multivariate analyses incorporating standard clinical measures of renal damage and novel biomarkers of LN would lead to an improved decision support tool for predicting outcomes in LN treatment. 112 For this study, urine samples from 140 patients with biopsy-proven LN were assembled spanning 4 patient cohorts including (1) the Medical University of South Carolina, (2) the Hopkins Lupus Cohort, (3) the LUNAR study by Genentech, and (4) the Abatacept in LN study by Bristol-Myers Squibb. All patients met the 1997 update of the revised ACR criteria for SLE and patient samples had to be collected from within 2 months of baseline. Patients had to have (1) biopsy-proven active class II, III, IV, or V nephritis or (2) newly active nephritis (either 500 mg increase in urine protein in 24 hours urine collection or a spot urine protein to creatinine ratio of 0.5). The patient design included 26% (37/140) complete responders (as defined by LUNAR trial parameters 113 and 74% (103/140) nonresponders. Over 50 serum and urinary clinical values were assessed including 46 urinary biomarkers spanning markers of resident and inflammatory cell activation (cytokines), chemokines, growth factors, and damage to resident cells were quantified by multiplexed bead assays or enzymatic assays.
Univariate analyses by receiver operating characteristics (ROC) curves were used to assess individual markers for significance to response to therapy. ROC plots are a visual representation of the surrogate biomarker(s) performance as a classifier to define true positive (sensitivity) and false positive (1-specificity). The AUC for the ROC plot may be interpreted in terms of sensitivity (true positive) and 1-specificity (false positive) for sample classification. A perfect biomarker would have a ROC AUC equal to 1.0 while a biomarker with the same sensitivity as a random coin toss would have a ROC equal to 0.5. In this study, the best 5 discriminating variables (ROC 0.57À0.67 and P value < 0.05) were urinary protein to creatinine ratio, estimated glomerular filtration rate, OPN, interleukin-2 receptor-a, and interleukin-8 (IL-8). Given the weak classification aspects of these ROC values the authors assess the classification performance of traditional markers (serum C3, C4, creatinine, antidsDNA antibody, and 24-hour protein or protein-to-creatinine ratio) with or without the additional novel biomarkers using multivariate (machine learning models based on Random Forest (RF) algorithms) models. The sensitivity of the combined marker group improved from an AUC of 0.32 (poor sensitivity for true positive and better than average sensitivity for false positive classification) to a better performing classifier-0.76. While a common cutoff for acceptable ROC values for good vs poor models is 0.7, the preponderance of FDA-approved tests for kidney damage have ROCs in excess of 0.8 [114] [115] [116] However, the combination of novel biomarkers to traditional markers did not improve the specificity. The improved sensitivity could be demonstrated with a minimal set of 4 markers (OPN, interleukin-2 receptor-a, IL-8, and TWEAK) plus the standard markers. OPN has been described as increased in patients with active LN. 117 TWEAK may have a role as both a biomarker and therapeutic target as described earlier in this manuscript.
Urine protein fragments. Progression of LN toward ESKD often proceeds with episodic and punctuated jumps through flare events. Ultimately the kidney suffers from both dysregulated glomerular and tubulointerstitial extracellular matrix remodeling. A window into that remodeling can be opened through direct mass spectrometric analysis of the low molecular weight urine proteome. This approach has been referred to most often as peptidomics as well as fragmentomics and degradomics. Wei et al used a capillary electrophoresis-MS method to analyze the urine of 71 SLE patients including 35 that had renal involvement and 36 that had no renal involvement. 118 These data were compared against the urine peptidome of 58 healthy controls. The abundances of »300 urinary peptides including 70 collagen fragments were significantly associated with LN. Using a web-tool (Proteasix, proteasix.com) built to compare experimental peptide data against the peptidase motifs within the MEROPS Peptidase database, the authors were able to hypothesize the contributions of 14 specific proteases as being responsible for production of the collagen peptide fragments. Nine proteases differentiated the collagen peptides observed for the SLE + LN vs the SLE ¡ LN samples. Twenty-eight collagen peptides have some value as surrogate diagnostic markers as they correlated to at least on clinical or histologic metric of renal damage. These data provide a very promising future for the use of urinary peptidomics as a clinical measure of renal damage in SLE patients. Moreover, these results suggest the activity of matrix metalloproteinase may be associated with the development of LN and hence represent targets for drug development.
Urine microRNA. Urine is a biofluid rich in prospective sources of surrogate biomarkers. 119 Mature microRNAs are small single-stranded RNA 22À25nt oligomers that function to influence gene expression and regulation. 120 Extracellular microRNAs are thought to be stabilized outside cells by either forming a stable RNA:protein complex or residing in the lumen of extracellular vesicles. 121 Cardenas-Gonzales et al examined urinary microRNA as a noninvasive biomarker of kidney pathology using diabetic (n = 58) and LN (n = 89) chronic kidney disease (CKD) cohorts with comparison to healthy controls (n = 93 and 119, respectively). 122 The significant features (using Ct scores <28) for disease state associated microRNA differences included both increased and decreased abundances compared to healthy controls. But when considering both microRNA abundances with CKD (>3-fold for LN and >10-fold diabetes) and receiver operator classification (c-statistics >0.85) it was observed the strongest CKD associating features for diabetic (miR-2681, riR-1915-3p, and miR-4532) and lupus (miR-3201 and miR-1273e) microRNA did not overlap. Correlation analysis for these microRNAs with patient suggested the diabetic alterations were most significantly associated with estimate glomerular filtration rate and interstitial fibrosis/atrophy while the LN was associated with endocapillary glomerular inflammation. Validation cohorts were used to verify and confirm expression differences of the diabetic markers between diabetic nephropathy vs diabetics without CKD and between LN and SLE patients. Finally the authors conducted experiments to confirm expression of microRNA in healthy renal tissue. The diabetic microRNAs were observed in the cytoplasm and nucleus in the glomerular and tubular compartments. While the LN-associated miR-3201 was not detected, miR-1273e was detected in the nuclei of the tubular epithelium. These data suggest the progression toward CKD in lupus may be associated with defects in micro-RNA regulation of gene expression.
Urine cells. Given that cells can be shed into the urine and these cells may reflect the underlying activation status of the kidney, Olivares et al use the cell pellet of an SLE cohort to quantify mRNA (quantitative reverse transcriptase-polymerase chain reaction) and protein (immunoblot) levels of SIRT1.
123 SIRT1 is categorized as a histone deacetylase that requires NAD+ for enzymatic function (Class III histone deacetylase). SIRT1 plays a variety of roles in gene expression through regulating the transcriptionally permissive state of chromatin and data from mouse studies of SLE suggests a plausible role in human disease. 124 Olivares demonstrated that both SIRT1 mRNA and protein were increased in the cell pellets of patients with active disease as compared to those patients in remission or healthy controls and correlated with anti-dsDNA antibody levels, histologic features of proliferative disease, and renal injury. 123 Ikuma et al demonstrated that the level of urinary podocytes and urinary podocalyxin (with normalization to urine creatinine) strongly correlated with histologic measure of LN in patients with active disease as compared to no renal involvement or health controls. 125 Urinary podocytes to creatinine levels were most strongly associated with the activity index and cellular crescents. Urinary podocalyxin to creatinine was highest in proliferative LN and membranous LN. The combination of both markers was associated with pure class V LN, which is often characterized by nephrotic syndrome and significant podocyte injury. These results show an intriguing association of transcriptionally permissive states with response disease activity/renal damage and likely associated with the podocyte.
GENE SPECIFIC BIOMARKERS
Defining genetic variants that reliably predict susceptibility or risk for development or progress and response to current, standard treatment of LN is invaluable toward improvement of patient care. These noninvasively measurable variants could serve as diagnostic tools and the known molecular and cellular pathways they mediate provide mechanistic targets for development of improved therapeutics.
Investigation of genetic variants contributing to SLE goes back nearly 2 decades, linking polymorphisms in major histocompatibility complex to LN. 126 The completion of the human Genome Project in 2003 launched an era of genome-wide-association studies (GWAS) to identify genetic variants in specific disease cohorts. In the following years, a number of GWAS studies of relatively small cohorts of SLE patients from mostly Japanese, Chinese, or European populations reported variants for IRF5, STAT4, ITGAM, BANK1, IRAK1, TNFAIP3, IL-18, Fcgamma Receptors, and Compliment factors. [127] [128] [129] [130] [131] [132] Harley et al published a more comprehensive review of the genes and polymorphisms discovered during this time period in 2009. 133 They summarized that these genes fall into 3 general regulatory categories (immune-complex processing, immune signal transduction, and TLR-IFN pathway). That same year, 2 hallmark, large-scale SLE GWAS studies were reported, 1 with a Chinese Han population and the other mostly an American cohort that included SLE patients of European, Asian, Hispanic, and African Ancestry. 134, 135 The Chinese Han study genotyped 1047 cases and 1205 controls and replicated 78 polymorphisms in 2 independent cohorts with 3152 cases and 7050 controls. The American study included 1963 cases and 4329 controls. Together, these studies confirmed most of the previous variants that had been reported for the smaller cohort studies and identified several new genes including PRDM1, JAZF1, VHRF1BP1, Il10, IKZF1, RASGRP3, SLC15A4, and TNIP1. The common new gene identified in both studies was TNIP1. TNIP1 encodes the protein ABIN1 that functions as a physiological inhibitor of NFkB and MAPK signaling. [136] [137] [138] [139] Our group found that transgenic mice globally expressing an inactivating ABIN1 mutation (ABIN1 [D485N] ) spontaneously developed systemic autoimmunity and progressive GN. 140, 141 We recently reported that glomerular expression of this inactive ABIN1 leads to increased glomerular inflammation and proteinuria in mice with acute anti-GBM GN. 142 In the following years, a number of groups investigated association of some of these genes and different polymorphisms with development of LN. Several of those variants with replicate, confirmed association with LN will be discussed. Our group genotyped 5 SNPs in TNIP1 (rs4958881, rs2233287, rs7708392, rs999556, and rs17728338) that were previous identified in SLE, systemic sclerosis, or psoriasis, in SLE patients with and without nephritis from the Large Lupus Association Study 2 143 and found a strong associations with LN at rs7708392 in European Americans and rs4958881 in African Americans. 141 Two different groups reported a strong association with the ITGAM allele rs1143679 and LN, a study with 910 SLE Chinese patients living in Hong Kong that was replicated in 278 Thai SLE patients and a study with 2366 SLE patients of European Ancestry. 144, 145 Large-scale genotyping of 8329 SLE patients (European-derived, Hispanic, African-American, and Asian) for 16 confirmed SLE susceptibility loci also found that risk alleles in ITGAM associated with LN. 146 Li et al reported that the Fcgamma receptor type IIIA V/F158 polymorphism was highly associated with LN in Asian and European decent individuals. 147 A meta-analysis of genetic data from 1453 Caucasian SLE patients found that patients with a TNFAIP3 rs5029939 risk allele had a higher risk of developing LN. 148 Lin et al evaluated 167 variants spanning MYH9 for association with LN in multiethnic American SLE patient samples and found that MYH6 rs2157257 associated with LN in a European-American population. 149 Significant association was reported for 2 TNFSF4 polymorphisms (rs2205960 and rs10489266) is a study of 814 Chinese SLE patients. 150 A study of 534 African American SLE patients with and 534 without LN showed that the APOL1 nephrology risk alleles G1/G2 strongly impact the risk of LN-ESRD in African Americans. 151 The identified genetic risks for LN and their clinical application were thoroughly reviewed in 2015 by Munroe and James and in 2017 by Iwamoto and Niewold. 152, 153 The 2015 review lists over 50 disease susceptibility genes associated with LN and grouped them into 5 regulatory systems (program cell death, immune complex clearance, intrarenal pathogenesis, innate immunity, and adaptive immunity). The 2017 review describes 11 confirmed susceptibility loci associated with LN (major histocompatibility complex [HLA-DR], ITGAM, FcgammaIIA and IIIA, IRF5, TNIP1, STAT4, TNFSF4, APOL1, PDGFRA, and HAS2) and focused on their roles in innate and adaptive immunity and intrarenal inflammation. Of note, they describe a T Cell function for TNIP1, but we recently reported involvement of TNIP1 in intrarenal inflammation as well. 154 Perhaps many of these genes have multiple functions in the pathogenesis of LN.
Interestingly, APOL1, PDGFRA, and HAS2, which appear to all function in intrarenal inflammation, are genes with newly discovered association with LN, but have not been associated with SLE. Another gene of this type is PLA2R1. PLA2R1 was identified as the major target antigen for membranous nephropathy 155 and a PLA2R1 variant RS4664308 was reported previously to associate with membranous nephropathy 156 in a European population also had a strong association with LN in a cohort of 1247 Chinese Han SLE patients. 157 In closing, it is clear that genetics plays an important factor in the development of LN. In fact, a recent biostatistics study of large-scale SLE genotyping data estimated the explained heritability for LN is 47% according to a Random Forests Prediction Model. 158 However, how can these susceptibility genes and variants be used for reliable diagnosis of LN? Perhaps this will require the use of a panel of confirmed variants and consideration of the ethnicity of the population for which the association was made and that of the patient being monitored. An important next direction in this process is to determine if progression of disease or response to current standard treatment can be predicted by genetic variants. Last, information pertaining to known functions of these associated susceptibility genes could be used to design novel therapies.
CONCLUSIONS
Several novel biomarkers for LN have been proposed in recent years, yet none have become incorporated into clinical use. 119 The failure of LN biomarkers to make it to the clinical arena is in part due to the fragmented nature in which they have been studied. The majority of studies have been single center with significant variability in cohorts, assays, and sample storage, leading to inconclusive results. Multicenter longitudinal studies, utilizing standardized storage methods and assays, are needed to develop more robust clinical biomarkers.
It has become clear that no single biomarker is likely to be sufficient to diagnose LN flares, and define the response to therapy and prognosis. A more likely scenario is a panel of urine, serum, tissue, and genetic biomarkers. Each biomarker "panel" will provide unique insight into different clinical questions: a genetics panel may identify whether a patient with SLE is likely to develop nephritis and which inflammatory pathways are likely to be active; a urine biomarker panel may help distinguish between inflammation and fibrosis, eliminating the need for repeat biopsies; a serum biomarker panel may identify nephritogenic autoantibodies that increase in flare and decrease in response to treatment. A more systematic approach involving multiple cohorts needs to be utilized so that precision medicine becomes a reality in LN.
